Join the Wegovy group to help and get support from people like you.
Wegovy News (Page 10)
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
TUESDAY, July 23, 2024 – The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 diabetes, a new study f...
Only One-Quarter of Patients Still Taking Semaglutide for Weight Loss Two Years Later
FRIDAY, July 12, 2024 – Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight loss,...
GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D
THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...
Only 1 in 4 Still Taking Ozempic, Wegovy for Weight Loss Two Years Later
THURSDAY, July 11, 2024 – Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows. Conducted by Prime...
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...
Semaglutide Cuts MACE in People With Overweight, Obesity, Regardless of HbA1c
TUESDAY, July 9, 2024 – Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic...
Wegovy, Ozempic Lower Risk of Many Obesity-Related Cancers
MONDAY, July 8, 2024 – In yet another finding that touts the health benefits of wildly popular weight-loss medications like Wegovy and Ozempic, scientists report that taking the drugs may help...
Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (s...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
FDA Approves Once-Weekly Wegovy injection for the Treatment of Obesity in Teens Aged 12 Years and Older
New indication based on clinical trial that demonstrated a 16.1% reduction in body mass index (BMI) in teens with obesity treated with Wegovy® (semaglutide) injection 2.4 mg compared to placebo ...
FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injec...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction